An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Sierra Oncology to Present at HC Wainwright BioConnect Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Sierra Oncology, Inc. (NASDAQ: SRRA) has announced its participation in the virtual 2022 HC Wainwright BioConnect Conference from January 10-13, 2022. CEO Stephen Dilly will present an overview of the company, available on demand starting at 7:00 am ET on January 10. A replay will be accessible for 90 days via the Investors section of Sierra's website. Sierra focuses on delivering targeted therapies for rare cancers, leveraging scientific expertise to transform cancer treatment paradigms.
Positive
None.
Negative
None.
SAN MATEO, Calif.--(BUSINESS WIRE)--
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 HC Wainwright BioConnect Conference being held virtually from January 10-13, 2022. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra, will provide an overview of the company in a presentation that will be available on demand beginning at 7:00 am ET on Monday, January 10 to conference attendees.
A replay of the presentation will be available following the conference on the Investors section of Sierra’s corporate website in the Events & Webcast tab. The replay will be available for approximately 90 days following the presentation.
About Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Together we are transforming promise into patient impact.